Advertisement
A Q&A with the Head of Surgical Oncology
When Cleveland Clinic’s new Taussig Cancer Center opened in March 2017, it introduced an innovative model of patient-centric cancer care.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
At first, the model didn’t seem more efficient for physicians, admits Brian Burkey, MD, Head of Surgical Oncology at Cleveland Clinic’s Head and Neck Institute.
“Patients used to come to us,” Dr. Burkey says. “The new center positions us to provide care differently and allows us to think differently about care.”
Just how differently? Dr. Burkey explains in this Q&A.
Dr. Burkey: Planning the new Taussig Cancer Center was in the works for years. Our No. 1 priority was to make it patient-centered — a one-stop shop for cancer care. And that’s what we’ve achieved. Except for major operations requiring general anesthesia, patients have all cancer services at the center — including imaging and pre- and post-op visits.
Patients see all of their doctors together instead of running from one floor to the next or taking a shuttle from one building to another. They sit in one room and see their doctors back to back to back.
Medical and radiation oncology live in the cancer center. Surgery still lives elsewhere, but a head and neck surgeon is always on site. We rotate.
Dr. Burkey: Yes, the new center is helping speed care decisions as well as interventions.
Before the new building opened, I might get a call about a PET scan showing something in a patient’s neck. We’d schedule a surgical consult. Now I get tapped on the shoulder so we can look at the scan together and, if needed, prepare for a biopsy right then. We often can do ultrasound-guided biopsies and open biopsies there instead of in the general OR, which can save weeks of waiting.
Advertisement
Or, let’s say a patient is referred to me for surgery, but I think they’re better suited for chemotherapy or radiation. Instead of advising them to make an oncology appointment, I can walk across the hall, talk to a medical or radiation oncologist, and have them see the patient immediately. That happens at least once a week!
Dr. Burkey: Our head and neck team is more tightly knit now that medical oncology, radiation oncology and surgery all share the same workspace. Working in close proximity is a benefit — especially with communication.
Maybe a medical oncologist will be talking about a tongue cancer patient, and I mention that the case reminds me of another I just saw. Maybe that inspires someone else to do a study. And maybe a resident who has been listening in wants to get involved with the study. We used to have conversations like that in our weekly tumor boards or quarterly research meetings. Now we have them continuously.
Dr. Burkey: We literally designed our exam rooms from scratch. We incorporated new video systems for endoscopies and ENT-designed patient chairs.
Personnel-wise, we added a head and neck patient navigator. Every morning, we have a team huddle to review patient cases and talk about who needs to be seen sooner or moved up in the OR. What used to require lots of time, emails and phone calls between doctors, nurses and admins now takes 10 minutes with all of us standing there.
Only a portion of my practice is cancer, so I only have one clinic day per week at Taussig Cancer Center. But if it were up to me, I’d be there every day. It’s such a great environment to work in.
Advertisement
Dr. Burkey is Vice Chairman and Section Head of the Section of Head and Neck Surgery and Oncology at the Cleveland Clinic Head and Neck Institute. He also serves as Medical Director of the Center for Consumer Health Information.
Advertisement
Advertisement
Soft tissue pathologist discusses research into incorporating genomic data to improve risk stratification
Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel
Findings strengthen evidence for risk-reducing procedures
Findings from large database important to inform clinical practice
Socioeconomic disparities have a notable influence on access to allogeneic hematopoietic cell transplant